Multiple sclerosis

Philips teams with SyntheticMR to deliver breakthrough AI-based quantitative brain imaging in MR to advance neurology care for patients

Retrieved on: 
Friday, March 1, 2024
MRI, Acquisition, CE, White matter, Myenteric plexus, 2D, AI, Traumatic brain injury, Magnetic resonance imaging, FDA, Synthetic, Cerebrospinal fluid, 3D, Neurodegenerative disease, TBI, Radiology, Multiple sclerosis, DSM-IV codes, PHG, Quant, Health, Patient, Dementia, Diagnosis, Software, AEX, Brain, Medical imaging

As healthcare providers strive to deliver high-quality care to patients, at #ECR2024 Philips is partnering with its customers to improve productivity and access to more sustainable healthcare.

Key Points: 
  • As healthcare providers strive to deliver high-quality care to patients, at #ECR2024 Philips is partnering with its customers to improve productivity and access to more sustainable healthcare.
  • Philips' exclusive agreement with SyntheticMR makes it the only company currently able to offer SyMRI NEURO 3D capability on MR scanners.
  • Accurate measurement of the volume and distribution of different tissue types in the brain is important for diagnosing brain disease.
  • "Smart Quant allows for shorter exams and exploration of quantitative metrics, which show great potential to better stratify patients with similar imaging characteristics on conventional MR sequences.

Tandem Cycling Linked to Improved Health for Those with Parkinson's, Care Partners

Retrieved on: 
Thursday, February 29, 2024
Social media, Television, Nervous system, Alzheimer's disease, Doctor of Philosophy, Quality of life, Walking, Stroke, Communication, Annual general meeting, DSM-IV codes, Perception, AAN, Health, Migraine, Parkinson's disease, Multiple sclerosis, University, Virtual reality, Depression, Concussion, Epilepsy, Disease, Brain, Prisma, Research, American Academy, Pharmaceutical industry

"It is just as important that care partners also receive care, so that is why we included them as the cycling partner.

Key Points: 
  • "It is just as important that care partners also receive care, so that is why we included them as the cycling partner.
  • The study included 18 participants, nine with Parkinson's disease and their corresponding nine care partners.
  • For the tandem cycling program, pairs of people with Parkinson's disease and their care partners cycled on indoor, stationary tandem bicycles while using a virtual reality platform two times per week for eight weeks.
  • The tandem cycling set-up also allowed the care partners to help adjust the cycling pace and facilitate a higher pedaling rate for greater health benefits.

New Study Finds Link Between Health Care Disparities and Stroke Treatment

Retrieved on: 
Thursday, February 29, 2024
Social media, United States census, Nervous system, Alzheimer's disease, Doctor of Philosophy, Research, Education, Kahathuduwa, Stroke, Master of Philosophy, Thrombolysis, Health, Annual general meeting, DSM-IV codes, Migraine, AAN, Multiple sclerosis, Parkinson's disease, Medicare, Employment, Concussion, Epilepsy, Medicaid, Brain, Housing, Insurance, American Academy

The study looked at people with ischemic stroke, which is caused by a blockage of blood flow to the brain and is the most common type of stroke.

Key Points: 
  • The study looked at people with ischemic stroke, which is caused by a blockage of blood flow to the brain and is the most common type of stroke.
  • The study involved 63,983 people with ischemic stroke identified through public health records in Texas.
  • Researchers then looked at social factors that may impact a person's health, such as income, education, housing, and access to health services.
  • Further studies are needed to investigate this connection between society, the health care system, and stroke outcomes.

Dynamic Access Launches Dynamic Infusion, a Specialty Home Infusion Nursing Provider

Retrieved on: 
Wednesday, February 28, 2024
Multiple sclerosis, Patient, Crohn's disease, Organization, Pharmacy, Haemophilia, Rheumatoid arthritis

DALLAS, Feb. 28, 2024 /PRNewswire/ -- Dynamic Access, LLC (Dynamic Access), a leading provider of vascular access solutions, has announced the launch of a new affiliate brand, Dynamic Infusion, which will provide home infusion nursing services for patients with chronic conditions such as autoimmune disorders, hemophilia, Crohn's disease, rheumatoid arthritis, multiple sclerosis and more.

Key Points: 
  • DALLAS, Feb. 28, 2024 /PRNewswire/ -- Dynamic Access, LLC (Dynamic Access), a leading provider of vascular access solutions, has announced the launch of a new affiliate brand, Dynamic Infusion, which will provide home infusion nursing services for patients with chronic conditions such as autoimmune disorders, hemophilia, Crohn's disease, rheumatoid arthritis, multiple sclerosis and more.
  • The Dynamic Infusion brand will support the operations of two legacy companies, each with more than a decade of experience delivering home infusion nursing services to patients throughout the Northeast: Infusion Ventures in New England, and NursePro in the Mid-Atlantic.
  • Peter Harris, CEO of Dynamic Access will also serve as CEO of Dynamic Infusion.
  • "The recent addition of NursePro expands our portfolio of specialty nursing solutions, expands our geographical footprint, and expands the number of lives we serve with life-changing care."

Study Finds Pesticide Use Linked to Parkinson's in Rocky Mountain, Great Plains Region

Retrieved on: 
Tuesday, February 27, 2024
Social media, Air pollution, Rocky Mountains, Nervous system, Research, Alzheimer's disease, Doctor of Philosophy, Pesticide, Barrow Neurological Institute, Record, Stroke, Risk, Annual general meeting, DSM-IV codes, Simazine, AAN, Migraine, Multiple sclerosis, Parkinson's disease, Concussion, Atrazine, Herbicide, Disease, Epilepsy, Brain, American Academy, Agriculture

In the Rocky Mountain and Great Plains region, we identified 14 pesticides associated with Parkinson's disease."

Key Points: 
  • In the Rocky Mountain and Great Plains region, we identified 14 pesticides associated with Parkinson's disease."
  • Krzyzanowski said the region included parts of Colorado, Idaho, Kansas, Montana, Nebraska, Nevada, New Mexico, North Dakota, Oklahoma, South Dakota, Texas, Utah and Wyoming.
  • They found that the pesticides and herbicides simazine, atrazine and lindane had the strongest relationship with Parkinson's disease.
  • A limitation of the study was that it relied on the use of county-level estimates since person-level information on pesticide exposure was not available for the study population.

Coeptis Therapeutics Adds Autoimmune Indications to Exclusive License Agreement with University of Pittsburgh for SNAP-CAR T and SNAP-CAR NK

Retrieved on: 
Monday, February 26, 2024
Division, Woman, Autoimmune disease, Assistant, Pain, CD19, Multiple sclerosis, University, Therapy, Rheumatoid arthritis, Immunology, Death, Patient, Autoimmunity, NK, Nature Communications, Infection, University of Pittsburgh, Research, Cancer, Vaccine

WEXFORD, Pa., Feb. 26, 2024 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases, today announced that it has expanded its exclusive license agreement with the University of Pittsburgh to include autoimmune indications as part of its ongoing development of SNAP-CAR T and SNAP-CAR NK.   This amended agreement builds upon the original exclusive license agreement with the University of Pittsburgh for SNAP-CAR T Cells, a "universal" CAR T technology platform designed to target multiple antigens simultaneously and potentially address a range of hematologic and solid tumors, and a recent amendment to the agreement for SNAP-CAR NK, an allogeneic natural killer (NK) cell therapy platform.

Key Points: 
  • WEXFORD, Pa., Feb. 26, 2024 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases, today announced that it has expanded its exclusive license agreement with the University of Pittsburgh to include autoimmune indications as part of its ongoing development of SNAP-CAR T and SNAP-CAR NK.
  • Autoimmune diseases, including systemic lupus erythematosus, rheumatoid arthritis, and multiple sclerosis, are known to result from autoreactive B cells.
  • "We are again excited to expand our license with Coeptis," said Jason Lohmueller, Ph.D., Assistant Professor of Surgery and Immunology in the Division of Surgical Oncology Research, University of Pittsburgh.
  • According American Autoimmune Related Disease Association , there are more than 100 autoimmune diseases impacting 1 in every 5 Americans, 75% of whom are women.

Hall of Fame College Football Coach, Mark Richt, Becomes Honorary Chair Role for Atlanta Neuroscience Foundation's 22nd Annual Charity Golf Tournament at TPC Sugarloaf Golf Club

Retrieved on: 
Thursday, February 22, 2024
Alzheimer's disease, Research, Education, Movement disorder, Golf, Communication, University, ANF, Honorary, Multiple sclerosis, University of Miami, Parkinson's disease

The event is set to take place at the prestigious TPC Sugarloaf Golf Club on Monday, September 23, 2024.

Key Points: 
  • The event is set to take place at the prestigious TPC Sugarloaf Golf Club on Monday, September 23, 2024.
  • This historic record of success, combined with his commitment to community service, makes him an excellent fit for the role.
  • Coach Richt expressed his enthusiasm about being part of this noble cause, stating, "I am honored to serve as the Honorary Chair for the Atlanta Neuroscience Foundation's Annual Charity Golf Tournament.
  • Participants will have the opportunity to interact with Coach Richt and enjoy a round at TPC Sugarloaf Golf Club, one of the country's preeminent golf courses.

Press Release: Phase 2 data published in NEJM show potential of frexalimab as high-efficacy therapy in relapsing MS

Retrieved on: 
Thursday, February 15, 2024
Week, Railway Workers' Union (Austria), Headache, Consortium, Multiple sclerosis, Sanofi, COVID-19, AFL, Patient, Plasma, Medical imaging

Findings also showed both doses of frexalimab provided significant reduction in new or enlarging T2 lesions, a secondary endpoint of the study.

Key Points: 
  • Findings also showed both doses of frexalimab provided significant reduction in new or enlarging T2 lesions, a secondary endpoint of the study.
  • Frexalimab is Sanofi’s novel second-generation investigational anti-CD40L antibody that has a unique method of action with the potential to address both acute and chronic neuroinflammation in MS without causing lymphocyte depletion.
  • “These published Phase 2 results for frexalimab represent important data in not only the potential treatment of MS but to the broader MS community.
  • Sanofi has initiated Phase 3 clinical trials of frexalimab in relapsing MS and non-relapsing secondary progressive MS.

Alarming Study Reveals Safety Limits are Exceeded for Mercury Exposure from Dental Amalgams in Pregnant Women in the U.S.

Retrieved on: 
Wednesday, February 14, 2024
Woman, Oral medicine, Alzheimer's disease, NHANES, Pregnancy, National Health, FDA, Dentist, International Academy, Risk, Multiple sclerosis, Safety, Health, Menopause, Parkinson's disease, Patient, DSM-IV codes, Policy, Mercury, Research, Composite, Gold

This study presents groundbreaking findings on the mercury vapor exposure from dental amalgams of pregnant women in the United States.

Key Points: 
  • This study presents groundbreaking findings on the mercury vapor exposure from dental amalgams of pregnant women in the United States.
  • In women with amalgam surfaces, the number of surfaces, correlated with significantly higher median daily urinary mercury excretion compared to women without amalgams.
  • Notably, close to 30% of these women received daily mercury vapor doses from amalgams exceeding the safety limits set by the U.S. Environmental Protection Agency.
  • Mercury amalgam dental fillings should be banned by the FDA as they pose a serious risk to the health of all individuals who have amalgam fillings, especially pregnant women and those of reproductive age."

ZyVersa Therapeutics Highlights Review Article Substantiating That Inflammasome Activation Is Pathogenic in Multiple Neurological Diseases

Retrieved on: 
Wednesday, February 14, 2024
Inflammasome, PD, NLRC4, ALS, ASC, Inflammation, Traumatic brain injury, Nature Reviews Neurology, Neurology, Extracellular space, Neuropathology, Stroke, TBI, NLRP1, Multiple sclerosis, Intellectual disability, Therapy, Super Meat Boy, DSM-IV codes, Epilepsy, AIM2, Brain, Pharmaceutical industry

The review article summarizes data demonstrating that inflammation resulting from activation of more than one type of inflammasome contributes to development of neurological diseases and that ASC specks lead to their progression.

Key Points: 
  • The review article summarizes data demonstrating that inflammation resulting from activation of more than one type of inflammasome contributes to development of neurological diseases and that ASC specks lead to their progression.
  • ZyVersa is developing IC 100, a monoclonal antibody targeting inflammasome ASC and ASC specks from multiple types of inflammasomes to block initiation and perpetuation of damaging inflammation.
  • (Nasdaq: ZVSA or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, highlights data from a review article published in Nature Reviews Neurology.
  • The authors concluded, “Use of inflammasome-targeted therapeutic approaches could improve existing therapeutic strategies for multiple neurological conditions.” To review the publication, Click Here .